Recently, we provided evidence for CTLA4 methylation to serve as a predictive biomarker for anti-PD-1 and anti-CTLA-4 ICB in patients with metastatic melanoma and metastatic clear cell renal cell carcinoma [21–23]. This evidence concerns the gene CTLA4 and metastatic melanoma.